STATESVILLE, N.C., March 11, 2026 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its third quarter ended January 31, 2026.
Fiscal Year 2026 Third Quarter Results:
Sales during the third quarter of fiscal year 2026 were $69,399,000, an increase of 3.3% compared to sales of $67,167,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,604,000 compared to $1,275,000 for the prior year quarter, an increase of 25.8%. Net earnings were $692,000 compared to net earnings of $1,354,000 for the prior year quarter. EBITDA1 for the quarter was $3,795,000 compared to $3,734,000 for the prior year quarter. Diluted earnings per share were $0.23 compared to diluted earnings per share of $0.45 in the prior year quarter.
The Company's order backlog was $183.2 million on January 31, 2026, as compared to $221.6 million on January 31, 2025, and $214.6 million on April 30, 2025.
Domestic Segment - Domestic sales for the quarter were $50,953,000, a decrease of 2.0% from sales of $51,976,000 in the prior year quarter. Domestic segment net earnings were $2,290,000 compared to $2,876,000 in the prior year quarter. Domestic segment EBITDA was $4,096,000 compared to $5,249,000 for the prior year quarter. Segment profitability was impacted during the period by lower manufacturing volumes across the laboratory construction portion of the business.
International Segment - International sales for the quarter were $18,446,000, an increase of 21.4% from sales of $15,191,000 in the prior year quarter. International segment net earnings were $1,256,000 compared to $476,000 in the prior year quarter. International segment EBITDA was $1,963,000 compared to $760,000 for the prior year quarter. International profitability increased when compared to the prior year period due to higher billings, principally in the Indian market.
Corporate Segment – Corporate segment pre-tax net loss was $3,059,000 for the quarter, as compared to a pre-tax net loss of $3,025,000 in the prior year quarter. Corporate segment EBITDA for the quarter was ($2,264,000) compared to corporate segment EBITDA of ($2,275,000) for the prior year quarter. Corporate segment EBITDA remained relatively flat as the Company continues to make strategic investments in people, processes, and technology to further build out its Corporate platform and support continued growth.
Total cash on hand on January 31, 2026, was $10,347,000, as compared to $17,164,000 on April 30, 2025. Working capital was $54,793,000, as compared to $58,441,000 at the end of the third quarter last year and $64,651,000 on April 30, 2025.
The Company had short-term debt of $7,351,000 as of January 31, 2026, as compared to $4,773,000 on April 30, 2025. Long-term debt was $42,316,000 on January 31, 2026, as compared to $60,730,000 on April 30, 2025. The building lease from the Company's December 2021 sale-leaseback transaction accounts for $25,988,000 of the long-term debt on January 31, 2026, and $26,632,000 of the long-term debt on April 30, 2025. Long-term debt, net of the sale-leaseback transaction, was $16,328,000 on January 31, 2026, as compared to $34,098,000 on April 30, 2025. The Company's debt-to-equity ratio on January 31, 2026, was 0.68-to-1, as compared to 0.99-to-1 on April 30, 2025. The Company's debt-to-equity ratio, net of the sale-leaseback transaction, on January 31, 2026, was 0.31-to-1, as compared to 0.57-to-1 on April 30, 2025.
"Following the successful turnaround of the business, we embarked on a strategy that accelerated inorganic growth, which led to the successful completion of the Company's acquisition of Nu Aire," said Thomas D. Hull III, Kewaunee's President and Chief Executive Officer. "Since then, our teams have worked diligently to integrate Nu Aire into the Kewaunee family and position the business for meaningful growth and EBITDA contribution. We have also continued to invest in our corporate platform to support the next phase of our inorganic growth strategy. These investments include strengthening our corporate team, implementing a robust financial consolidation system, and enhancing our readiness to comply with the SEC's accelerated reporting requirements."
"As is traditionally the case," Hull continued, "our third quarter results often represent our softest quarter due to the impact of the holiday schedule in the United States, a general slowdown of construction schedules in the winter months, and customers looking to wrap up any construction projects before the calendar year-end. This trend was further exacerbated by significant geopolitical and economic uncertainty, and by the volatility in project delivery timelines that we have previously discussed. Although the construction-related portion of our business has been soft this fiscal year, the addition of Nu Aire's end-user containment products has helped offset that softness. This dynamic validates our growth and diversification strategy and underscores the strength and resilience of our now broader laboratory products portfolio."
"I am proud of how our team has responded to a year of challenging global dynamics. That our company was still able to deliver year-over-year growth on an as-reported basis underscores the value of our strategy and our commitment to long-term value creation."
______________________ |
1 EBITDA is a non-GAAP financial measure. See the table below for a reconciliation of EBITDA and segment EBITDA to net earnings (loss), the most directly comparable GAAP measure. |
EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA Reconciliation (Unaudited) ($ in thousands)
| ||||||||
Quarter Ended January 31, 2025 | Domestic | International | Corporate | Consolidated | ||||
Net Earnings (Loss) | $ 2,876 | $ 476 | $ (1,998) | $ 1,354 | ||||
Add/(Less): | ||||||||
Interest Expense | 322 | 26 | 789 | 1,137 | ||||
Interest Income | (1) | (130) | (81) | (212) | ||||
Income Taxes | 638 | 281 | (1,027) | (108) | ||||
Depreciation and Amortization | 1,414 | 107 | 42 | 1,563 | ||||
EBITDA | $ 5,249 | $ 760 | $ (2,275) | $ 3,734 | ||||
Professional Fees2 | 1,012 | — | 982 | 1,994 | ||||
Adjusted EBITDA | $ 6,261 | $ 760 | $ (1,293) | $ 5,728 | ||||
Quarter Ended January 31, 2026 | Domestic | International | Corporate | Consolidated | ||||
Net Earnings (Loss) | $ 2,290 | $ 1,256 | $ (2,854) | $ 692 | ||||
Add/(Less): | ||||||||
Interest Expense | 307 | 16 | 789 | 1,112 | ||||
Interest Income | (2) | (117) | (15) | (134) | ||||
Income Taxes | 22 | 711 | (205) | 528 | ||||
Depreciation and Amortization | 1,479 | 97 | 21 | 1,597 | ||||
EBITDA | $ 4,096 | $ 1,963 | $ (2,264) | $ 3,795 | ||||
Professional & Other Fees3 | — | — | 189 | 189 | ||||
Adjusted EBITDA | $ 4,096 | $ 1,963 | $ (2,075) | $ 3,984 | ||||
Year to Date January 31, 2025 | Domestic | International | Corporate | Consolidated | ||||
Net Earnings (Loss) | $ 10,271 | $ 1,295 | $ (5,011) | $ 6,555 | ||||
Add/(Less): | ||||||||
Interest Expense | 1,176 | 66 | 809 | 2,051 | ||||
Interest Income | (1) | (437) | (410) | (848) | ||||
Income Taxes | 2,643 | 807 | (2,450) | 1,000 | ||||
Depreciation and Amortization | 2,736 | 317 | 131 | 3,184 | ||||
EBITDA | $ 16,825 | $ 2,048 | $ (6,931) | $ 11,942 | ||||
Professional & Other Fees2 | 1,012 | — | 3,253 | 4,265 | ||||
Adjusted EBITDA | $ 17,837 | $ 2,048 | $ (3,678) | $ 16,207 | ||||
Year to Date January 31, 2026 | Domestic | International | Corporate | Consolidated | ||||
Net Earnings (Loss) | $ 10,609 | $ 2,540 | $ (6,919) | $ 6,230 | ||||
Add/(Less): | ||||||||
Interest Expense | 931 | 39 | 2,261 | 3,231 | ||||
Interest Income | (4) | (428) | (54) | (486) | ||||
Income Taxes | 2,482 | 1,435 | (1,713) | 2,204 | ||||
Depreciation and Amortization | 4,366 | 292 | 68 | 4,726 | ||||
EBITDA | $ 18,384 | $ 3,878 | $ (6,357) | $ 15,905 | ||||
Professional & Other Fees3 | — | — | 763 | 763 | ||||
Adjusted EBITDA | $ 18,384 | $ 3,878 | $ (5,594) | $ 16,668 | ||||
_____________________ |
2 Professional and other fees incurred during the three and nine months ended January 31, 2025 related to the Company's acquisition of Nu Aire, Inc. ("Nu Aire"), which closed on November 1, 2024 |
3 Professional and other fees incurred during the three and nine months ended January 31, 2026 related to the Company's integration of its newly acquired subsidiary, Nu Aire |
Adjusted Consolidated Statement of Operations Reconciliation (Unaudited) ($ in thousands, except per share amounts) | |||||||
Three Months Ended January 31, | |||||||
As Reported | Professional & | Adjusted | Adjusted | ||||
Net sales | $ 69,399 | $ — | $ 69,399 | $ 67,167 | |||
Cost of products sold | 50,854 | — | 50,854 | 47,934 | |||
Gross profit | 18,545 | — | 18,545 | 19,233 | |||
Operating expenses | 15,963 | 189 | 15,774 | 14,469 | |||
Operating profit | 2,582 | 189 | 2,771 | 4,764 | |||
Other income, net | 134 | — | 134 | 162 | |||
Interest expense | (1,112) | — | (1,112) | (1,137) | |||
Profit before income taxes | 1,604 | 189 | 1,793 | 3,789 | |||
Income tax (benefit) expense | 528 | 44 | 572 | 502 | |||
Net earnings | 1,076 | 145 | 1,221 | 3,287 | |||
Less: Net earnings attributable to the non-controlling interest | 384 | — | 384 | 29 | |||
Net earnings attributable to Kewaunee Scientific Corporation | $ 692 | $ 145 | $ 837 | $ 3,258 | |||
Net earnings per share attributable to Kewaunee Scientific Corporation stockholders | |||||||
Basic | $ 0.24 | $ 0.05 | $ 0.29 | $ 1.13 | |||
Diluted | $ 0.23 | $ 0.05 | $ 0.28 | $ 1.09 | |||
Nine Months Ended January 3 | |||||||
